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Introduction
A wide variety of core-shell magnetic iron oxide (magnetite) 
nanoparticles (MNPs) has been designed up to date for the aims of 
magnetic imaging (magnetic resonance imaging, MRI; magnetic 
particle imaging, MPI), magnetic hyperthermia and targeted drug 
delivery [1-10]. The combined use of MNPs in both diagnosis and 
therapy (called theranostics) exploits the superparamagnetic property 
of nano-sized magnetite (also called SPION, “superparamagnetic iron 
oxide nanoparticle”) and its specific surface properties that allow easy 
surface modification by physical or chemical adsorption of different 
organics. The shell around the core particles ensures colloidal stability 
and salt tolerance, which are necessary to prevent aggregation in 
the biological environment. In addition, the coating layer can host 
biologically active molecules such as drugs and targeting agents. 
Using surface-polymerized gallic acid (PGA) as protecting shell 
of nanoparticles can be highly advantageous in biomedicine, because 
gallic acid (GA) is not only biocompatible but also bioactive. GA is one 
of the most important antioxidant components of a healthy diet. The 
anti-inflammatory, antibiotic, antifungal and anticancer effects of GA 
are well known as well as its role in preventing cardiovascular diseases 
and neurodegenerative disorders [11-15]. Many GA-like compounds 
(phenolic acids) are present in large concentrations in different plants 
[16]. GA has been used as a model for food polyphenols [17] and the 
concentration of dietary polyphenols is often expressed in gallic acid 
equivalents. GA-like compounds are also used in biomedicine as drugs 
for toxic metal removal due to their capability of chelating heavy metal 
and transition metal ions [18]. Their application for curing degenerative 
diseases is promising, because they can cross the blood brain barrier 
and chelate toxic ions in the brain thus preventing or even inverting the 
formation of plaques [13,14]. When attached to magnetic nanoparticles, 
the curing efficiency can be enhanced via magnetic targeting. 
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Abstract
Polyacid covered core-shell iron oxide nanoparticles were designed for potential use in biomedicine with special 
attention to theranostics - magnetic resonance imaging (MRI), magnetic hyperthermia and magnetic drug targeting. The 
magnetite nanoparticles coated with a gallic acid shell polymerized in situ on the nanoparticle surface (PGA@MNPs) 
were tested for hemocompatibility in blood, sedimentation rate, blood smear and blood cell viability experiments and for 
antioxidant capacity in Jurkat cells in the presence of H2O2 as reactive oxygen species. No signs of interaction of the 
nanoparticles with whole blood cells were found. In addition, the PGA@MNPs reduced significantly the oxidative stress 
mediated by H2O2 supporting earlier findings of MTT tests, namely, the improvement of cell viability in their presence. 
The in vitro tests revealed that PGA@MNPs are not only biocompatible but also bioactive. Preliminary experiments 
revealed that the nanoparticles are especially efficient MRI and magnetic hyperthermia agents. The r2 relaxivity was 
found to be one of the highest among published values (387 mM-1s-1) and they possess a relatively significant specific 
absorption rate (SAR) value of 11 W/g magnetite.
We prepared GA-coated magnetite nanoparticles and allowed 
surface-induced polymerization to proceed during the course of five 
weeks resulting in PGA-coated MNPs (PGA@MNP). Our hypothesis 
was that the autogenic polymerization of GA catalyzed by the surface 
of MNPs should proceed similarly to the known natural process of 
humic matter formation on the surface of clay minerals, the precursor 
molecules of which are structurally similar to GA [19]. This way, 
the synthesis of PGA@MNPs would proceed in an all-natural soft 
method and the emergence of toxic by-products would be excluded. 
The PGA@MNPs have indeed been successfully produced and we 
have published their physico-chemical and colloidal characterization 
relevant to possible biomedical applications [20-22]. In the present 
study, we utilized in vitro experiments for testing the biodistribution, 
biocompatibility and antioxidant capacity of the polygallate stabilized 
SPION product. In addition, we studied the MRI contrasting and 
hyperthermia efficiency of the coated MNPs.
Materials and Methods
FeCl2·4H2O, FeCl3·6H2O (Molar, Hungary), gallic acid (GA, Carlo 
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Erba) and NaCl, NaOH and HCl (Molar, Hungary) to set the ionic 
strength and pH in the experiments were analytical grade reagents. 
Ultrapure water (18 MΩ) from a HumanCorp Zeneer water purification 
system was used in the experiments. 
Magnetite (Fe3O4) nanoparticles were synthesized by alkaline 
hydrolysis of iron(II) and iron(III) salts [22]. Briefly, the concentrated 
iron salt solutions were mixed at the ratio of 1:2 and precipitated by 
NaOH solution. We washed and acidified the formed MNPs in order 
to fully disperse them in the aqueous medium, then dialyzed against 1 
mM HCl solution and stored in the dark at 4oC. 
The PGA@MNPs for the biomedical tests were prepared on the 
basis of GA adsorption experiments detailed by us earlier [21,22]. The 
PGA@MNP dispersions were prepared at a concentration of 15 g/L in 
aqueous medium. The pH of magnetite dispersions was adjusted to ∼6.5 
and GA was added in concentration of 0.6 mmol GA/g magnetite. The 
pH was readjusted subsequently for five weeks, during which period 
GA polymerized at the surface as it is demonstrated in [21,22]. The 
sample was stored in dark at 4oC. The values of electrokinetic potential 
(-40 mV), hydrodynamic diameter (∼170 nm, as compared to that of 
naked MNPs of ∼100 nm) and critical coagulation concentration (500 
mM, while that of naked MNPs of is only 1 mM) revealed the presence 
of a thick coating layer, which in turn, stabilizes the particles even in 
the presence of salt at high concentrations. TEM pictures of naked and 
PGA-coated MNPs are given in Seciton 1 of Supplementary material 
(Figures S1 and S2) demonstrating also the formation of a thick PGA 
coating. Particles with not fully polymerized GA shell (GA@MNPs) 
were also characterized earlier [21,22]. Although they were found to be 
highly biocompatible (cell viability inhibition < 5%), their low colloidal 
stability made them inapplicable for biomedical application.
Interaction of PGA@MNPs with HeLa cells
The accumulation of PGA@MNPs at the surface of or inside cancer 
cells was tested via examining their interaction with HeLa cells in a cell 
culture within 48 hours using Prussian blue staining. The procedure is 
described in detail in [22]. 
Hemocompatibility tests 
Hemocompatibility of PGA@MNPs, i.e. their interaction with 
human blood was studied in erythrocyte sedimentation rate (ESR) 
experiments utilizing a Sedi-15 automated sedimentation rate 
measuring device (BD Inc., Franklin Lakes, NJ, USA) and Seditainer 1.8 
vacutainer tubes (BD Inc., USA) as given in our previous publication 
[22]. PGA@MNP samples were mixed at room temperature with 
citrate-, and EDTA-anticoagulated blood of three healthy donors 
(Donors #1-#3) to achieve a PGA@MNP concentration of 0.32 mg/mL. 
Peripheral blood smear tests of the whole blood (EDTA-
anticoagulated) of the donors were carried out by an automated 
slide preparation system (Sysmex SP4000i) at room temperature 
using the May-Grünwald Giemsa (MGG, Biolyon, Dardilly, France) 
staining technique in a  CellaVisionTM DM96 automation device 
(CellaVision AB, Ideon, Science Park, Lund, Sweden) as detailed in 
[22]. The influence of PGA@MNPs on platelet aggregation was studied 
at a concentration of 0.32 mg/mL. The acquisition and classification 
software of the instrument was used to differentiate the normal and 
abnormal cells (white blood cells (WBC), red blood cells (RBC) and 
platelets (PLT)).
Blood cell viability measurements
WBC viability factor (WVF), i.e., the fraction of viable WBCs present 
in the sample was determined by CELL-DYN Sapphire hematology 
analyser (Abbott Diagnostics, USA). This routine diagnostic method 
is used to differentiate the necrotic, apoptotic and normal cells in 
EDTA-anticoagulated blood based on the selective staining of nuclei 
of damaged or nonviable cells with a cell membrane impermeable 
fluorescent dye, propidium iodide. After hydrodynamic focusing, 
WVF was determined by the emitted red fluorescence (at 617 nm) of 
the dye bound to the nucleic acid of injured or dead cells. The effect 
of PGA coated nanoparticles on WBC viability was examined at 37°C. 
PGA@MNP concentration in blood was 0.4 mg/mL. The WVF values 
were determined 10, 30, 60, 90, 120, 180 and 240 minutes after mixing 
the MNPs with the blood of Donors #1-#3 at a final concentration of 
0.4 mg PGA@MNP/mL. The accuracy of the measured WVFs is above 
97% as calculated from 5 parallel runs. The cell count of WBC, RBC 
and PLT comprising all viable, damaged and dead cells was determined 
by impedance measurements in the same samples. The impedance 
measurements were also used for determination of the volumes of 
thrombocytes and red blood cells.
Determination of antioxidant capacity
The non-adherent human T-cell leukemia cell line Jurkat (DSMZ 
ACC 282) was used for in vitro experiments. The cells were cultured 
in RPMI medium supplemented with 10% fetal calf serum and 1 % 
glutamine (all from Thermo Fisher Scientific, Waltham, MA, USA) 
under standard cell culture conditions in a humidified incubator at 
37°C and 5% CO2. For the experiments, the cells were counted and 
their viability was determined using MUSE Cell Analyzer (Merck 
Millipore, Billerica, MA, USA). The antioxidative capacity of free 
GA and PGA@MNPs was determined according to the following 
procedure. Intracellular oxidative stress was determined using 
2′,7′-Dichlorofluorescein diacetate (DCFH-DA, Sigma-Aldrich, 
Taufkirchen, Germany). The cells were adjusted to a density of 5×105 /
mL in PBS (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and 
pre-incubated with 20 µM DCFH-DA for 30 minutes at 37°C. Then 
the cells were washed once with PBS and subsequently incubated in 
cell culture medium with free GA or PGA@MNPs in the indicated 
concentrations for 1 h at 37°C without further washing steps. As an 
oxidizing agent H2O2 (Roth, Karlsruhe, Germany) was added to the 
cells for further 2 h at 37°C. Then the cells were analyzed using a Gallios 
flow cytometer (Beckman Coulter, Fullerton, CA, USA). Intracellular 
DCF fluorescence (excitation at 488 nm and emission at 525 nm) was 
measured by gating of morphologically viable cells. Data analysis was 
performed with Kaluza software version 2.0 (Beckman Coulter).
MRI studies 
The MRI contrast enhancement efficiency of the PGA@MNP 
was studied by determining the T1 (longitudinal) and T2 (transversal) 
relaxation times and calculating r1 and r2 relaxivities as described in our 
previously published paper [23] by using a clinical MRI instrument 
GE Excite HDxt (GE Medical Systems, Milwaukee, WI) at magnetic 
field strength of 1.5 T. The contrast enhancement of coated particles 
was measured using the standard “birdcage” head coil. The MNP 
dispersions were prepared at nominal Fe concentrations of 0.009, 
0.018, 0.045, 0.09, 0.135, 0.18 and 0.22 mM and the exact iron content 
of the samples was measured by inductively coupled plasma (ICP) 
method using an Optima 7000 DV ICP-OES instrument (Perkin-
Elmer, Shelton, CT, USA). 4 mL of samples was placed in a plastic box 
filled with water and put in the centre of the head coil. The r1 and r2 
relaxivities were determined as the slopes of the 1/T1 and 1/T2 vs. Fe 
concentration plots to quantify the contrast enhancement efficiency of 
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the PGA@MNPs. The quality of fitting was estimated by the coefficient 
of determination (R-squared).
Hyperthermia experiments 
The magnetic hyperthermia efficiency of PGA@MNPs was tested 
in a magneThermTM (nanoTherics Ltd., Keele, Staffordshire, UK) 
instrument. The volume of the MNP dispersion was 4 mL, and the 
concentration 15 g/L. The measurements were performed at a resonant 
frequency of 110.7 kHz in a magnetic field of B=25 mT (H=19.9 kA/m, 
17 turn coil and 200 nF capacitor). The measurement time in the 
hyperthermia setup was 15 minutes and the specific absorption rate 
(SAR, W/g magnetite) values for the initial rate of temperature change 
were calculated according to the approximating equation (Eq.1):
SAR=(cp,s mwater /mPGA@MNP) (ΔT/Δt)                                 (1)
where cp,s is the specific heat capacity of the medium (water), mwater 
and mPGA@MNP are the masses of the medium and the nanoparticles, 
respectively, and ΔT/Δt is the initial temperature rate.
Results and Discussion
Interaction of PGA@MNPs with Hela cells
The Prussian blue staining method allowed detecting the 
distribution of PGA@MNPs in the matrix of a HeLa cancer cell culture. 
As it is seen in Figure 1, the particles contacted with the cancer cells 
intimately either by adsorbing at the outer surface or by penetrating 
into the cytoplasm.  The adsorption was observed as the presence of 
particle agglomerates linked to the cells. In case of penetration, the 
nuclei remained unstained. Both types of interaction are advantageous 
for the medical use of the particles. The attachment to the surface and 
internalization identify the cancer cells in MRI and localize the heat 
production in hyperthermia. The PGA@MNPs can also be used for 
targeting specific anticancer drugs, which extends their potential use 
in the wider field of theranostics. The tendency of cells to internalize 
negatively charged core-shell nanoparticles, such as GA@MNPs at 
physiological pH [20], has been reported frequently [24]. 
Hemocompatibility of PGA@MNPs 
Three standard in vitro assays [25,26], blood sedimentation (i.e., 
erythrocyte sedimentation rate, ESR), smear and WBC viability tests 
were used to assess the hemocompatibility of PGA@MNPs. Blood 
sedimentation experiments were performed with citrate-anticoagulated 
blood samples to examine whether the coated magnetic nanoparticles 
induce RBC aggregation or not. Although the citrate anticoagulant 
seems to induce thrombocyte aggregation [22], it can be safely used 
for blood sedimentation rate measurements in accordance with the 
daily laboratory routine, since it does not influence the sedimentation 
of RBCs. In addition, the thin and long citrate-anticoagulated test 
tubes are suited well for visual observations similarly to the EDTA-
anticoagulated tubes, but use significantly smaller sample volume. 
Representative sedimentation results are shown in Figure 2. The height 
of the settled RBCs is virtually the same both in the absence and the 
presence of PGA@MNPs, but a brownish colour appeared in the 
plasma after addition of PGA@MNPs. Similar effect was found for 
other types of polyacid-coated MNPs as well [22,27]. The recorded ESR 
values coincide in the absence and presence of coated MNPs (11 and 8 
mm/h, respectively) within the formal accuracy of the measurements 
±3 mm/h. The same RBC sedimentation feature was observed in 
EDTA-anticoagulated test tubes as well. The presence of PGA@MNP 
did not influence the aggregation of RBCs in either of the experiments. 
The same picture was observed previously when GA-coated MNPs (GA 
adsorbed but not polymerized) were added to whole blood samples 
[22], with ESR value of 9 mm/h. This suggests that hemocompatibility 
is determined by the chemistry of the surface of MNPs but does not 
depend on the thickness of the coating layer. 
Peripheral blood smear tests were performed to study the influence 
of MNPs on platelet aggregation. EDTA-anticoagulated blood 
samples were used to exclude thrombocyte aggregation observed 
previously in citrate-anticoagulated blood [22]. The morphological 
analysis of human blood cells showed neither deformation nor 
decomposition of RBCs in the presence of PGA coated nanoparticles. 
As it is seen in Figure 3, no aggregation of RBCs was detected revealing 
excellent hemocompatibility of PGA@MNPs comparable to that 
of other polyacid- [22,27], polyethylehene oxide (PEG)- [23] and 
Figure 1: Prussian blue staining of HeLa cell culture. (A) Control and (B) 
PGA@MNP loading at 7.35 mg/mL concentration.
Figure 2: Blood sedimentation test of native blood sample of Donor #3 (left) 
and of blood-PGA@MNP mixture at 0.32 mg/mL PGA@MNP concentration 
(right).
Figure 3: Microscopic pictures of the blood smears prepared from EDTA-
anticoagulated blood of Donor #3 (A) without and (B) with PGA@MNPs.
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dehydroascorbic acid (DHA)- [28] coated MNPs. Similar pictures were 
taken for all the three donor’s blood. 
The effect of PGA@MNP on viability of white blood cells (WBCs) 
was tested by measuring the viability factor (WVF) and the results 
obtained for the blood of Donor #3 are demonstrated in Figure 4. The 
viable fraction of WBCs of EDTA-coagulated native blood decreased 
from 0.99 to 0.97 after 240 minutes, which is a spontaneous process 
in in vitro experiments. The oxygen and nutrients concentration of 
blood decreases with time initiating a gradual cell death right after the 
sample collection [26]. The PGA coated nanoparticles were dispersed 
in an aqueous medium and so the effect of the added water on the 
WBC viability was studied as well. Addition of ultrapure water induced 
a decrease in WVF from 0.98 to 0.91 within 240 minutes. The dilution 
caused a stronger decrease in WVF as compared to the undiluted 
sample probably due to the decrease in the osmotic pressure and an 
additional decrease in nutrient content [26]. No further change in 
the time-dependence of WVF was observed upon addition of PGA@
MNP revealing the excellent hemocompatibility of the PGA coated 
nanoparticles. The relatively empty right region of scatter plot of the 
blood containing PGA@MNPs (inset of Figure 4) shows that only 
negligible amount of necrotic and apoptotic cells are present in the 
sample. The same picture was observed for the water-diluted blood 
sample, indicating that WBC viability was influenced by dilution, but 
not by the presence of PGA coated nanoparticles. Similar results were 
obtained for the blood samples of Donors #1 and #2.
Exploiting the multichannel structure of the CELL-DYN Sapphire 
hematology analyzer, we investigated the change in the cell counts 
of RBC, WBC and PLT in parallel as a function of time, dilution and 
PGA@MNP addition. The results are shown in Figure 5. The total 
amount of the three blood components did not change significantly 
during the 240 minutes of the experiment, indicating the stability of 
the blood sample for the time of inspection. Dilution with ultrapure 
water reduced the cell count values of WBC, RBC and PLT and the 
decrease coincided well with the degree of dilution (16%) for all three 
components. Dilution with PGA@MNP dispersion led to the same 
∼16% decrease in the cell counts evidencing that the presence of the 
nanoparticles did not affect the stability of the sample.
The mean platelet volume (MPV=8.47 ± 0.2 10-15 L) did not change 
with time in the blood-PGA@MNP mixture, which also supports the 
results from smear experiments that no thrombocyte aggregation 
occurred in the presence of PGA coated nanoparticles. However, a 
slight increase was observed in the mean RB cell volume over time (Δ 
MCV ∼2%, from 87.9 to 90.0 10-15 L) indicating that swelling took place 
during the experiments. This can be explained either by the change 
in the osmotic conditions after dilution or by thermal instability of 
RBCs as the temperature-dependence of their swelling property was 
observed in other human studies as well [29]. The hemocompatibility 
experiments, altogether, did not show any tendency for PGA@MNPs 
to interfere negatively with any of the blood components considered 
in our experiments. This evidence of hemocompatibility makes the 
particles good candidates for use as MRI or drug targeting agents being 
injected intravenously. 
Antioxidant effect of PGA@MNPs
The effect of free GA or PGA@MNPs on the cellular morphology 
of Jurkat cells was analyzed in flow cytometry by means of forward 
scatter (FS) and side scatter (SS) (shown in Figure S3A,  Section 2 of 
Supplementary material), providing information about cellular size 
and granularity. Cells undergoing cell death change their morphology, 
reflected by scatter alterations [30], thus viable cells can be clearly 
separated from dying or dead cells [31]. Morphological analysis showed 
that treatment of Jurkat cells with low concentrations of H2O2 (25 µM 
and 50 µM) and/or GA solutions only induced minimal amounts of cell 
death during the observation period of 2 h. 
Intracellular oxidative stress was determined using the cell 
permeable non-fluorescent dye DCFH-DA, which is enzymatically 
hydrolyzed inside the cells by cellular esterases to non-fluorescent 
DCFH. In the presence of oxidative stress, DCFH is subsequently 
oxidized to fluorescent DCF [32]. To be sure that the DCF fluorescence 
is located inside the cells, only cells of the viable gate were considered for 
analysis of oxidative stress [33]. After treatment with H2O2, an increase 
in the DCF fluorescence was measured as a function of H2O2 and GA 
dosing. Pre-incubation of the cells with free GA significantly reduced 
the H2O2 mediated DCF fluorescence at all tested GA concentrations 
(shown in Figure S3B, Section 2 of Supplementary material), showing 
its antioxidative properties.
Next, the question arises whether PGA@MNPs also exhibit 
Figure 4: Time-dependent WBC viability in EDTA-anticoagulated blood with 
and without PGA@MNPs. Inset: Fluorescence scatter plot of blood samples 
with PGA@MNPs. FL3-DNA is the fluorescence intensity of DNA-bound 
propidium iodide and SIZE is cell size determined from intensity loss. The 
blue and red dots indicate different types of WBC. 
Figure 5: Time-dependent change in the cell count of WBCs (6.5-5×106 /L), 
RBCs (3.7-3.2×109 /L) and PLTs (2.4-2×104 /L) in the blood sample of Donor 
#3 without dilution and diluted with water and PGA@MNP dispersion at 37°C.
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antioxidative capacity or not. Since we speculated that GA might 
be less potent when immobilized on nanoparticles, we used only 
the higher nominal GA concentrations 25 µM and 50 µM added in 
the form of PGA@MNPs. The morphological analysis showed high 
biocompatibility of PGA@MNPs during the observation period of 2 
h (Figure 6A). After induction of oxidative stress using H2O2, a dose 
dependent increase in DCF fluorescence was observed. Adding free 
GA at 50 μM, as reference, reduced the fluorescence intensity similarly 
as in the above set of experiments using free GA as antioxidant. Two 
different PGA@MNP samples were used for the experiments. The first 
one contained free GA in the supernatant as a result of the adsorption/
polymerization process, i.e., dissolved GA in equilibrium with that on 
the surface of MNPs. Free GA, on the other hand, was removed from 
the second sample by washing. The PGA@MNP dispersions both with 
and without free GA reduced the H2O2 mediated oxidative stress as it is 
seen in Figure 6B. However, their effect was weaker as compared to that 
of free GA. In addition, PGA@MNPs with free GA in the supernatant 
showed a stronger antioxidative capacity than in the absence of that.
The observed antioxidative capacity of PGA@MNPs is in harmony 
with our earlier cell viability experiments performed with GA@MNPs 
on healthy and cancer cells MRC-5, HeLa and A431 for several types 
of polyacid-coated MNPs [21]. As compared to the cell inhibition 
values between 3 and 25% found for citrate, humate, polyacrylate 
and poly(acrylate-co-maleate) coated MNPs, for PGA@MNPs we 
have found negative values around -5% at the highest concentration. 
Thus, cell viability has even appeared to be enhanced in the presence 
of PGA@MNPs in the cell culture. This result becomes fully explicable 
after their antioxidant effect was experimentally proved in the present 
studies of oxidative stress reduction. 
MRI contrasting properties of PGA@MNPs 
The contrast enhancement efficiency of PGA@MNPs was tested in 
MRI measurements. The longitudinal and transverse relaxivity values 
(r1 and r2, respectively) were calculated by plotting the relaxation rates 
(R1=1/T1 and R2=1/T2) against the Fe concentration as described in our 
previous papers [23,34]. According to our expectations, small r1 value 
(1.8 mM-1s-1) was obtained for PGA@MNP, which is characteristic for 
superparamagnetic iron oxide nanoparticles (SPION) in general [23]. 
However, remarkable T2 contrast enhancement was recorded for the 
PGA coated MNPs, shown in Figure 7 as the concentration dependence 
of the R2 relaxation rate. The calculated value of transverse relaxivity 
was extremely high (r2 ∼387 mM-1s-1) exceeding the majority of data 
published for MNPs (50-306 mM-1s-1) [28,34-38]. Resovist (r2 306 mM-
1s-1) [34], in addition, is generally used as reference superparamagnetic 
iron oxide MRI contrast agent despite its FDA approval has not yet 
been completed [22]. The high transverse relaxivity of PGA@MNP is 
probably due the strong hydration of the highly negatively charged 
PGA shell near the magnetite core. The enhanced relaxation of large 
amount of protons near the MNP surface leads to the decrease in signal 
intensity and increase in the negative contrast [23]. The r2 relaxivity 
of PGA@MNPs ∼387 mM-1s-1 is somewhat lower than that of naked 
MNPs (measured at pH ∼4 as 429.5 ± 9.5 mM-1s-1 [34]). The naked 
MNPs can be stabilized only at low pH, where they hold positive 
charges due to the accumulation of protons directly on the MNP surface 
causing the large r2 relaxivity. In the same time, PGA-coated MNPs 
are negatively charged (stable in wide range of pH [20], necessary for 
biocompatibility) and they accumulate water dipoles somewhat farther 
from the MNP surface, where the effect of the local magnetic field on 
proton relaxation is weaker.
Magnetic hyperthermia efficiency of PGA@MNPs 
The heating effect of two different PGA coated samples was tested 
and compared to the result obtained for naked MNPs (Figure 8A). The 
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Figure 6: Reduction of H2O2mediated oxidative stress by PGA@MNPs. 
(A) Observed resistance of the cells to morphological changes induced by 
free GA, PGA@MNPs, or H2O2during the observation period of 2 h. (B) 
The changes in mean fluorescence intensity (MFI) of DCF measured in the 
population of morphologically viable cells in function of dosing of H2O2, free 
GA and PGA@MNPs.
 
Figure 7: Transverse relaxation rate (R2=1/T2) of the PGA@MNP sample as 
a function of iron concentration and the resulting r2relaxivity value. Inset: T2-
weighted image of samples in phantom water (TR=3000 ms, TE=40 ms, Fe 
concentration increases from left to right).
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gallic acid modified magnetite samples PGA@MNP (1) and PGA@
MNP (2) are two different lots produced by the same protocol detailed 
in the Materials and methods. The frequency and the field strengths 
(amplitude) of the alternate magnetic field were selected to be 
appropriate for medical application. The SAR of the MNP and PGA@
MNP samples were calculated from the slopes of the heating rate curves 
below the clear kinks in the PGA@MNP heating rate curves at 70-80 
seconds [39] as seen in Figure 8B. The obtained SAR values of all the 
dispersions were nearly identical, around 11 W/g magnetite. This value 
is fully consistent with others found in the literature, albeit the choice 
of the parameters of the magnetic field and the magnetization and 
particle size of the particles among its other relevant properties have 
tremendous effect on the SAR values [40-44]. The observed heating 
efficiency of our samples should be sufficient to rise temperature 
~5°C above body temperature necessary to induce apoptosis and 
necrosis of cells in the case when the same particle concentration  can 
be achieved by accumulating them in specific target locations during 
administration.
The finding that PGA coating did not alter the SAR of the MNPs 
is in agreement with the fact that the hyperthermic effect of the 
nanoparticles with ∼8 nm diameter is primarily via Neél relaxation 
[43], i.e., to the alteration of the direction of a single magnetic dipoles 
but not the particle as a whole. The coating shell could be expected to 
affect the heating rate in case of the Brownian type of relaxation or 
relaxation caused by the obvious magnetic hysteresis of larger magnetic 
particles.
Conclusions
We have performed in vitro biomedical testing of magnetite 
nanoparticles coated with gallic acid shell polymerized in situ at the 
surface of the particles in a soft and reagent-free process, similar to that 
of formation of humic matter in nature. The high chemical and colloidal 
stability of the particles (PGA@MNPs) were studied and discussed 
thoroughly in our previous publications [20-22], and the paper on the 
mechanism of surface polymerization of GA on MNPs is published 
in parallel [45]. The ease and low cost of preparation combined with 
the exceptional durability and stability of these particles make them 
superior candidates for biomedical applications.
A series of in vitro blood compatibility experiments (ESR, blood 
smears, viability tests of different particulate components of blood 
WBC, RBC and PLT) revealed that PGA@MNPs do not interact 
with whole blood, which make them promising candidates for 
designing intravenous injection formulations as MRI contrast or drug 
targeting agents. The significant antioxidant capability of the PGA 
 A B 
Figure 8: (A) Increase in the temperature of aqueous dispersions of naked 
and PGA-coated MNPs at particle concentration of 15 mg/mL measured in 
alternating magnetic field during 15 minutes. (B) The initial part of temperature 
increase. 
coating measured in ROS tests may be beneficial in the future in vivo 
applications. 
Measurements of r2 relaxivities for MRI and SAR values for 
hyperthermia applications proved the reliability of the use of PGA@
MNPs as theranostic agents in biomedicine. 
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